(Q38822416)

6 September 2017

title

Commercial pharmacogenetic-based decision-support tools in psychiatry (English)

1 reference

6 September 2017

main subject

decision support system

1 reference

Chad A Bousman

1

1 reference

6 September 2017

Malcolm Hopwood

series ordinal

2

1 reference

6 September 2017

publication date

25 April 2016

1 reference

6 September 2017

published in

The Lancet Psychiatry

1 reference

6 September 2017

volume

3

1 reference

6 September 2017

issue

6

1 reference

6 September 2017

page(s)

585-590

1 reference

Antidepressant pharmacogenetics

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Pharmacogenetics of response to antipsychotics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Using a pharmacogenomic algorithm to guide the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Meaningful use of pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Drug interactions with smoking

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

High impact child abuse may predict risk of elevated suicidality during antidepressant initiation

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

Cytochrome P450 pharmacogenetics in African populations: implications for public health

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2816%2900017-1

7 January 2021

10.1016/S2215-0366(16)00017-1

Identifiers

DOI

1 reference

6 September 2017

1 reference